After the sold-out success of Sensia, BEYOND Developments launches The Mural in Dubai Maritime City
BEYOND Developments, the fast-rising name in Dubai luxury real estate, has launched The Mural, its fourth project within its 8 million sq. ft Dubai Maritime City masterplan. A true design statement, The Mural blends architectural artistry with an extraordinary waterfront lifestyle offering investors high capital appreciation and unique luxury living that matches their aspirations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250404407930/en/
BEYOND Developments – The Mural (Photo: AETOSWire)
Building on the phenomenal success of its third project Sensia, sold out within two days of launch, The Mural marks another architectural and artistic triumph for BEYOND. A landmark addition to Dubai Maritime City, it redefines the relationship between nature and urban design, offering residents a tranquil waterfront environment while contributing to Dubai’s evolving real estate landscape.
Adil Taqi, Chief Executive Officer, BEYOND Developments, said: “Investor confidence in Dubai is unstoppable, as evidenced by its No. 1 FDI ranking for four consecutive years. We are responding with decisive action, securing prime strategic locations to fuel growth and deliver value. The rapid success of our projects so far, powered by a diverse international investor base, testifies to a dynamic trajectory inspired by our home city.”
BEYOND’s earlier projects including Saria, Orise, and Sensia, have consistently attracted discerning investors from across the MENA region, Europe, Asia, and America. This widespread interest reflects the strength of Dubai’s real estate sector and the growing recognition of BEYOND’s commitment to deliver visionary, design-led developments that stand out on the global stage. Dubai’s progressive regulatory framework and adoption of proptech innovations offer investors confidence and security, essential for significant capital deployment
Strategically positioned at the tip of Dubai Maritime City and adjacent to a master-planned forest, The Mural’s dual waterfront-and-greenery setting shaped the architectural design, which seamlessly integrates nature and urban living.
Taqi added: “The Mural reflects our commitment to innovation and excellence in waterfront living. Every aspect is meticulously designed to focus on maximizing the residential experience on an incredible site and raising the bar for Dubai’s luxury real estate sector.”
Designed by British architectural firm BENOY, The Mural’s striking silhouette comprises two interlocking volumes, tilted toward the water and forest. Lush landscaping is incorporated into the façade through planters, while generous terraces maximize natural light, views, and outdoor living.
The 36-storey tower offers a selection of 1, 2, and 3-bedroom apartments, duplexes, maisonettes, and a penthouse. The resort-style amenities for residents include a state-of-the-art gym, an infinity pool complex, landscaped terraces, BBQ and dining areas, and a dedicated yoga zone. Families benefit from children’s play areas and green spaces, while remote workers can utilize outdoor co-working areas. The Mural’s crown jewel, the Sky Terrace on level 32, offers Jacuzzis, tanning terraces, and sky dining.
The Mural is BEYOND’s fourth project and a testament to the company’s rapid growth and vision. It is scheduled for completion by Q2 2028.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404407930/en/
Contacts
Mariam Bouraoui
Account Manager
Tel. + 971 508997697
mariam@gambit.ae
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press Release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom